Abstract
To manage Wegener's granulomatosis (WG) effectively, the clinician must establish the diagnosis without delay, recognize variability in clinical course and severity, critically monitor disease activity, and anticipate disease-related and treatment-related morbidity. These issues represent the focus of approach to the diagnosis and treatment of WG.
MeSH terms
-
Antineoplastic Agents / therapeutic use
-
Biopsy
-
Granulomatosis with Polyangiitis* / diagnosis
-
Granulomatosis with Polyangiitis* / pathology
-
Granulomatosis with Polyangiitis* / therapy
-
Humans
-
Immunosuppressive Agents / therapeutic use
-
Immunotherapy
-
Prevalence
-
Tomography, X-Ray Computed
Substances
-
Antineoplastic Agents
-
Immunosuppressive Agents